NeuroDiagnostics (“NDx”) has the only minimally invasive highly accurate test, DISCERN™, for Alzheimer’s Disease. Multidisciplinary teams at the NIH and the Rockefeller Neurosciences Institute, led by Dr. Alkon, over the last 30 years led to the development of the three biomarkers. The three biomarkers comprise an AD-Index assay, a Morphometric Imaging assay, and a PKC Epsilon assay. FDA has granted NDx Breakthrough Status. Our diagnostic biomarkers have been confirmed by autopsy validation (NIH “Gold Standard”).
NeuroDex, Inc. is the leading neurological exosomal blood based diagnostics and companion diagnostics company. Utilizing ExoSORT™, its proprietary, specific, and robust platform for capturing and analyzing cell-specific exosomes in plasma, NeuroDex, has successfully identified Alzheimer’s patients and post-stroke cognitive impairment, stratified FTD patients and monitored the effect of potential therapies in the neurodegenerative space. The robustness of NeuroDex’s ExoSORT™ was demonstrated by several spike-in recovery experiments, as well as protein and RNA analysis.